456 Studies Now Enrolling
NRG-GY018: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER
Study of Pembrolizumab in Combination with Chemotherapy for Patients with Endometrial Cancer
| Sponsor: | NA |
| Enrolling: | Female Patients Only |
| IRB Number: | AAAS8334 |
| U.S. Govt. ID: | NCT03914612 |
| Contact: | Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
Additional Study Information:
We are doing this study because we want to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs is better or worse than the usual approach for your endometrial cancer. The usual approach is defined as care most people get for endometrial cancer.
This study is closed
